BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 1517372)

  • 1. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.
    Matikainen T; Ding YQ; Vergara M; Huhtaniemi I; Couzinet B; Schaison G
    J Clin Endocrinol Metab; 1992 Sep; 75(3):820-5. PubMed ID: 1517372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
    Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and alpha-subunit in postmenopausal women.
    Couzinet B; Lahlou N; Thomas G; Thalabard JC; Bouchard P; Roger M; Schaison G
    Clin Endocrinol (Oxf); 1991 Jun; 34(6):477-83. PubMed ID: 1716186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of a GnRH antagonist.
    Hall JE; Brodie TD; Badger TM; Rivier J; Vale W; Conn PM; Schoenfeld D; Crowley WF
    J Clin Endocrinol Metab; 1988 Sep; 67(3):524-31. PubMed ID: 3137243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins.
    Apter D; Bützow TL; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1993 Apr; 76(4):940-9. PubMed ID: 8473410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men.
    Pavlou SN; Veldhuis JD; Lindner J; Souza KH; Urban RJ; Rivier JE; Vale WW; Stallard DJ
    J Clin Endocrinol Metab; 1990 May; 70(5):1472-8. PubMed ID: 2110578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition.
    Kettel LM; Roseff SJ; Chiu TC; Bangah ML; Vale W; Rivier J; Burger HG; Yen SS
    J Clin Endocrinol Metab; 1991 Sep; 73(3):644-9. PubMed ID: 1908486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasts in the gonadotropin-releasing hormone dose-response relationships for luteinizing hormone, follicle-stimulating hormone and alpha-subunit release in young versus older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis.
    Zwart AD; Urban RJ; Odell WD; Veldhuis JD
    Eur J Endocrinol; 1996 Oct; 135(4):399-406. PubMed ID: 8921820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist.
    Daneshdoost L; Pavlou SN; Molitch ME; Gennarelli TA; Savino PJ; Sergott RC; Bosley TM; River JE; Vale WW; Snyder PJ
    J Clin Endocrinol Metab; 1990 Jul; 71(1):92-7. PubMed ID: 2115048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of serum immunoreactive luteinizing hormone and bioactive follicle-stimulating hormone by testosterone in early pubertal boys.
    Hassing JM; Padmanabhan V; Kelch RP; Brown MB; Olton PR; Sonstein JS; Foster CM; Beitins IZ
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1082-9. PubMed ID: 2108181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum.
    McLachlan RI; Cohen NL; Vale WW; Rivier JE; Burger HG; Bremner WJ; Soules MR
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1078-85. PubMed ID: 2498381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy.
    Huhtaniemi IT; Dahl KD; Rannikko S; Hsueh AJ
    J Clin Endocrinol Metab; 1988 Feb; 66(2):308-13. PubMed ID: 3123510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.